<?xml version='1.0' encoding='utf-8'?>
<document id="26180127"><sentence text="Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model."><entity charOffset="42-52" id="DDI-PubMed.26180127.s1.e0" text="Crizotinib" /></sentence><sentence text="An orally available multiple tyrosine kinase inhibitor, crizotinib (Xalkori), is a CYP3A substrate, moderate time-dependent inhibitor, and weak inducer"><entity charOffset="29-37" id="DDI-PubMed.26180127.s2.e0" text="tyrosine" /><entity charOffset="56-66" id="DDI-PubMed.26180127.s2.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.26180127.s2.e0" e2="DDI-PubMed.26180127.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26180127.s2.e0" e2="DDI-PubMed.26180127.s2.e1" /></sentence><sentence text=" The main objectives of the present study were to: 1) develop and refine a physiologically based pharmacokinetic (PBPK) model of crizotinib on the basis of clinical single- and multiple-dose results, 2) verify the crizotinib PBPK model from crizotinib single-dose drug-drug interaction (DDI) results with multiple-dose coadministration of ketoconazole or rifampin, and 3) apply the crizotinib PBPK model to predict crizotinib multiple-dose DDI outcomes"><entity charOffset="129-139" id="DDI-PubMed.26180127.s3.e0" text="crizotinib" /><entity charOffset="214-224" id="DDI-PubMed.26180127.s3.e1" text="crizotinib" /><entity charOffset="241-251" id="DDI-PubMed.26180127.s3.e2" text="crizotinib" /><entity charOffset="339-351" id="DDI-PubMed.26180127.s3.e3" text="ketoconazole" /><entity charOffset="355-363" id="DDI-PubMed.26180127.s3.e4" text="rifampin" /><entity charOffset="382-392" id="DDI-PubMed.26180127.s3.e5" text="crizotinib" /><entity charOffset="415-425" id="DDI-PubMed.26180127.s3.e6" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e0" e2="DDI-PubMed.26180127.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e1" e2="DDI-PubMed.26180127.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e2" e2="DDI-PubMed.26180127.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e2" e2="DDI-PubMed.26180127.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e2" e2="DDI-PubMed.26180127.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e2" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e2" e2="DDI-PubMed.26180127.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e3" e2="DDI-PubMed.26180127.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e3" e2="DDI-PubMed.26180127.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e3" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e3" e2="DDI-PubMed.26180127.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e4" e2="DDI-PubMed.26180127.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e4" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e4" e2="DDI-PubMed.26180127.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e5" e2="DDI-PubMed.26180127.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26180127.s3.e5" e2="DDI-PubMed.26180127.s3.e6" /></sentence><sentence text=" We also focused on gaining insights into the underlying mechanisms mediating crizotinib DDIs using a dynamic PBPK model, the Simcyp population-based simulator" /><sentence text=" First, PBPK model-predicted crizotinib exposures adequately matched clinically observed results in the single- and multiple-dose studies"><entity charOffset="29-39" id="DDI-PubMed.26180127.s5.e0" text="crizotinib" /></sentence><sentence text=" Second, the model-predicted crizotinib exposures sufficiently matched clinically observed results in the crizotinib single-dose DDI studies with ketoconazole or rifampin, resulting in the reasonably predicted fold-increases in crizotinib exposures"><entity charOffset="29-39" id="DDI-PubMed.26180127.s6.e0" text="crizotinib" /><entity charOffset="106-116" id="DDI-PubMed.26180127.s6.e1" text="crizotinib" /><entity charOffset="146-158" id="DDI-PubMed.26180127.s6.e2" text="ketoconazole" /><entity charOffset="162-170" id="DDI-PubMed.26180127.s6.e3" text="rifampin" /><entity charOffset="228-238" id="DDI-PubMed.26180127.s6.e4" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e0" e2="DDI-PubMed.26180127.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e0" e2="DDI-PubMed.26180127.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e0" e2="DDI-PubMed.26180127.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e0" e2="DDI-PubMed.26180127.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e0" e2="DDI-PubMed.26180127.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e1" e2="DDI-PubMed.26180127.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e1" e2="DDI-PubMed.26180127.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e1" e2="DDI-PubMed.26180127.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e1" e2="DDI-PubMed.26180127.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e2" e2="DDI-PubMed.26180127.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e2" e2="DDI-PubMed.26180127.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e2" e2="DDI-PubMed.26180127.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e3" e2="DDI-PubMed.26180127.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26180127.s6.e3" e2="DDI-PubMed.26180127.s6.e4" /></sentence><sentence text=" Finally, the predicted fold-increases in crizotinib exposures in the multiple-dose DDI studies were roughly comparable to those in the single-dose DDI studies, suggesting that the effects of crizotinib CYP3A time-dependent inhibition (net inhibition) on the multiple-dose DDI outcomes would be negligible"><entity charOffset="42-52" id="DDI-PubMed.26180127.s7.e0" text="crizotinib" /></sentence><sentence text=" Therefore, crizotinib dose-adjustment in the multiple-dose DDI studies could be made on the basis of currently available single-dose results"><entity charOffset="12-22" id="DDI-PubMed.26180127.s8.e0" text="crizotinib" /></sentence><sentence text=" Overall, we believe that the crizotinib PBPK model developed, refined, and verified in the present study would adequately predict crizotinib oral exposures in other clinical studies, such as DDIs with weak/moderate CYP3A inhibitors/inducers and drug-disease interactions in patients with hepatic or renal impairment"><entity charOffset="30-40" id="DDI-PubMed.26180127.s9.e0" text="crizotinib" /><entity charOffset="131-141" id="DDI-PubMed.26180127.s9.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.26180127.s9.e0" e2="DDI-PubMed.26180127.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26180127.s9.e0" e2="DDI-PubMed.26180127.s9.e1" /></sentence><sentence text="" /></document>